Wellness or medical product? In 2026, it’s all in the framing
The FDA's 2026 General Wellness guidance update changes the conversation for digital health teams. Here's what it means - and why it matters right now.
There's a question that comes up sooner or later in almost every digital health product conversation: where does wellness end and medical device territory begin?
For years, the honest answer was: it depends, and it's not entirely clear. Teams building consumer health products - apps that track heart rate, platforms that display blood pressure trends, services that surface stress or recovery scores - were often navigating a grey area. The technology was advancing faster than the regulatory language describing it.
That changed in January 2026, when the FDA released an updated version of its General Wellness Policy for Low Risk Devices. The update doesn't rewrite the rules but it does something arguably more valuable: it draws the line more clearly, particularly for products built on non-invasive physiologic sensing, like wrist-based wearables, camera-based monitoring, or optical sensors.
We explored this issue in depth in our latest report, Health data in the light of FDA's 2026 update, produced together with ROOK and Elevare Law. If you want the full picture now, you can download it here or read on for the key ideas.
.png)
The same measurement. Two different regulatory outcomes.
Here's the part that surprises most product teams when they first encounter it: the FDA's classification of your product doesn't primarily depend on what it measures. It depends on how those measurements are framed, communicated, and used.
A product that displays blood pressure trends alongside sleep and recovery data, in a wellness context, without referencing disease or diagnostic thresholds, can qualify as a general wellness product - no clearance required. The same measurement framed as a tool for identifying hypertension, shifts the product into regulated medical device territory.
That's a deliberate policy choice that reflects how these technologies actually function in the real world. And it has significant implications for how product teams, not just regulatory counsel, need to think about their work.
Why this matters beyond compliance
The regulatory boundary isn't just a legal consideration. It shapes what you can build, how quickly you can bring it to market, what claims you can make, and ultimately how users understand and trust your product.
For teams building in the wellness, preventive health, or corporate wellbeing space, the 2026 guidance opens meaningful room to deliver sophisticated physiologic insight as part of a wellness experience, without defaulting into a clinical clearance pathway.
But that room comes with conditions. The language in your UI, the framing in your marketing materials, the logic behind your alerts and notifications, the way you present individual values versus trends - all of these are now, in a real sense, regulatory instruments. A disclaimer at the bottom of the screen doesn't offset copy elsewhere that implies diagnostic intent. The FDA evaluates the totality of the product experience.
What's in the report
We put this report together to give digital health product teams a practical, grounded view of where things stand in 2026.
It draws on a live conversation with Jonas Dücker, COO of ROOK, one of the leading health data integration platforms in the market, who walks through what AI-ready data actually requires and where most teams get stuck. It includes expert legal commentary from Rebecca Gwilt of Elevare Law, who breaks down the 2026 FDA guidance in plain language, including the specific product design decisions that determine which side of the regulatory line you're on.
And it includes a practical set of recommendations: seven steps product teams can take right now to reduce regulatory risk, build with more confidence, and design for the long term.
If your product touches physiologic data in any form, whether you're building a wellness app, a corporate health platform, an insurance product, or a telehealth integration, the 2026 guidance is relevant to decisions you're making today.
More blog posts
Sagittis et eu at elementum, quis in. Proin praesent volutpat egestas sociis sit lorem nunc nunc sit.
What’s changing in women’s health - and what still isn’t
Despite growing investment in femtech, women’s health is still shaped by data gaps and system-level bias. This discussion explores how better data, thoughtful AI, and more intentional product design can move from tracking to real understanding.
The FDA's 2026 general wellness update and what it means for health monitoring
The FDA’s 2026 update expands what qualifies as general wellness, but applying it correctly is where most teams struggle. This webinar recap breaks down the key changes, common compliance pitfalls, and how product, marketing, and AI decisions shape regulatory risk in digital health.
How digital-first life insurers are rethinking underwriting
Digital underwriting often relies on self-reported data that limits accuracy from the start. This webinar recap explores how Lyfery integrated camera-based health measurement to improve data quality, strengthen risk models, and enable more reliable, behavior-based insurance.